Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 27, 2022 at 09:41 am
Share
Shanghai Rightongene Biotechnology Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 48.27 million compared to CNY 64.77 million a year ago. Revenue was CNY 48.27 million compared to CNY 64.77 million a year ago. Net loss was CNY 2.33 million compared to net income of CNY 16.38 million a year ago. Basic loss per share from continuing operations was CNY 0.04 compared to basic earnings per share from continuing operations of CNY 0.29 a year ago. Diluted loss per share from continuing operations was CNY 0.04 compared to diluted earnings per share from continuing operations of CNY 0.29 a year ago.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.